Coherus BioSciences Inc reports results for the quarter ended in December - Earnings Summary

Coherus Oncology

13/03/2024 21:01

* Coherus BioSciences Inc  CHRS.OQ  reported a quarterly
adjusted
loss of 62 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -60 cents.  The mean expectation of nine analysts for the
quarter was for a loss of 12 cents per share. Wall Street
expected results to range from -37 cents to 52 cents per share.
    * Revenue rose 101.8% to $91.52 million from a year ago;
analysts
expected $96.40 million. 
    * Coherus BioSciences Inc's reported EPS for the quarter was
a
loss of 71 cents​.
    * The company reported a quarterly loss of $79.65 million.
    * Coherus BioSciences Inc shares had fallen by 32.7% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 24.5%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Coherus
BioSciences Inc is $9.00 
This summary was machine generated from LSEG data March 13 at
09:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.12          -0.62          Missed
 Sep. 30 2023      -0.27          -0.27          Met
 Jun. 30 2023      -0.48          -0.38          Beat
 Mar. 31 2023      -0.57          -0.75          Missed